TP53 mutation screening for patients at risk of myeloid malignancy https://www.nature.com/articles/s41375-024-02283-x

Recommendations from the AML molecular MRD expert advisory board https://www.nature.com/articles/s41375-024-02275-x

Azacitidine and gemtuzumab ozogamicin as post-transplant maintenance therapy for high-risk hematologic malignancies https://www.nature.com/articles/s41409-024-02311-5

Allogeneic hematopoietic cell transplantation with sequential conditioning regimen in relapsed refractory acute myeloid leukemia https://www.nature.com/articles/s41409-024-02310-6

Selective haematological cancer eradication with preserved haematopoiesis https://www.nature.com/articles/s41586-024-07456-3